Pfizer’s coronavirus vaccine candidate enters first phase of US trials

The start of the US trial follows the first jabs administered in Germany last week

Pfizer - Pfizer’s coronavirus vaccine candidate enters first phase of US trials

Pfizer Inc. (NYSE:PFE) and BioNTech (NASDAQ:BNTX) announced the first US participants were administered their Covid-19 vaccine candidate.

The trials involve up to 360 healthy subjects into two cohorts, 18-55 and 65-85 years of age.

READ: Coronavirus: what’s happening in the labs of pharma companies worldwide

Another cohort of participants received a jab in Germany last week.

The phase 1/2 of the study determine the safety, immunogenicity and optimal dose level of four vaccine candidates in a single, continuous study.

“The short, less than four-month timeframe in which we’ve been able to move from pre-clinical studies to human testing is extraordinary and further demonstrates our commitment to dedicating our best-in-class resources, from the lab to manufacturing and beyond, in the battle against COVID-19,” said Albert Bourla, chairman and chief executive of Pfizer.

Shares in Pfizer were flat at US$79.93 in pre-market trading.

Quick facts: Pfizer

Price: 37.49 USD

Market: NYSE
Market Cap: $208.33 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Lotus Resources reveals highlights on scoping study at its Kayelekera...

Lotus Resources Ltd (ASX:LOT) Managing Director Eduard Smirnov tells Proactive the group's Kayelekera Uranium Project can be among first uranium projects to begin production to meet the impending uranium supply shortfall. Smirnov says according to the study, the project will have a long mine...

10 hours, 49 minutes ago

2 min read